Zoledronic acid
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer With Bone Metastasis
Conditions
Breast Cancer With Bone Metastasis
Trial Timeline
Aug 1, 2002 → —
NCT ID
NCT00372710About Zoledronic acid
Zoledronic acid is a phase 3 stage product being developed by Novartis for Breast Cancer With Bone Metastasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00372710. Target conditions include Breast Cancer With Bone Metastasis.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer With Bone Metastasis were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01197300 | Phase 3 | Completed |
| NCT01087008 | Approved | Completed |
| NCT01004510 | Phase 2 | Terminated |
| NCT00909961 | Phase 3 | Completed |
| NCT00966992 | Phase 2 | Terminated |
| NCT00760370 | Phase 2 | Completed |
| NCT00774020 | Approved | Completed |
| NCT00740129 | Approved | Completed |
| NCT00745485 | Approved | Completed |
| NCT00477217 | Phase 2 | Withdrawn |
| NCT00622505 | Approved | Completed |
| NCT00982124 | Phase 3 | Completed |
| NCT01218035 | Approved | Completed |
| NCT00434447 | Approved | Completed |
| NCT00424983 | Phase 1 | Completed |
| NCT00391950 | Phase 3 | Terminated |
| NCT00361595 | Pre-clinical | Completed |
| NCT00334139 | Approved | Completed |
| NCT00391690 | Approved | Completed |
| NCT00375427 | Phase 3 | Completed |
Competing Products
20 competing products in Breast Cancer With Bone Metastasis